Gland Pharma Limited Share Price & Stock Analysis

Gland Pharma Limited (NSE: GLAND, BSE: 543245) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹53,843 Cr, it ranks #198 by market cap among the 6,197 Indian listed companies on FinBizNet, and #11 of 86 in Medicinal Chemicals and Botanical Products. At ₹3,340.00 (as of 16 Nov 2026), the share price is 1.0% below its 52-week high of ₹3,374.00 and 112.3% above its 52-week low of ₹1,573.60. The share price is up 75.6% over one year and up 12.4% over three months.

Key Metrics

Current Price₹3,340.00
Market Cap₹53,843 Cr
NSE SymbolGLAND
BSE Code543245
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio53.1
Return on Equity10.53%
Return on Assets6.27%
52-Week Range₹1,573.60 – ₹3,374.00
1-Year Price Change+75.6%
3-Month Price Change+12.4%
Beta (1Y)0.44
Dividend Yield0.60%
HeadquartersHyderabad, Telangana
Websitewww.glandpharma.com

Latest Quarterly Results — Q2 FY27

Revenue₹1,834 Cr
Net Profit₹291 Cr
Net Margin15.9%
EPS (Basic)₹17.62
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Gland Pharma Limited Quarterly Revenue and Profit Trend

Gland Pharma Limited reported revenue of ₹1,834 Cr in Q2 FY27, up 23.3% from ₹1,487 Cr in Q2 FY26 and up 1.9% from ₹1,800 Cr in Q1 FY27. It posted a net profit of ₹291 Cr for the quarter, against a net profit of ₹184 Cr in Q2 FY26 (up 58.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,425 Cr (Q4 FY25) to ₹1,834 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹1,834 Cr₹291 Cr15.9%
Q1 FY27₹1,800 Cr₹317 Cr17.6%
Q4 FY26₹1,743 Cr₹367 Cr21.0%
Q3 FY26₹1,695 Cr₹261 Cr15.4%
Q2 FY26₹1,487 Cr₹184 Cr12.4%
Q1 FY26₹1,506 Cr₹215 Cr14.3%
Q4 FY25₹1,425 Cr₹187 Cr13.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 45.75% of Gland Pharma Limited's shares as of Sept 2026, against 51.83% in Sept 2025 (−6.08 percentage points). Delivery averaged 56.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Gland Pharma Limited

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma

Products and Services

1. Pharmaceuticals-This segment manufactures generic injectables.

Business Segments

1. Pharmaceuticals-100%

Gland Pharma Limited vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Gland Pharma Limited₹53,843 Cr53.110.53%₹1,834 Cr+75.6%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Gland Pharma Limited?

Gland Pharma Limited is trading at ₹3,340.00, with a market capitalisation of ₹53,843 Cr.

Which sector does Gland Pharma Limited belong to?

Gland Pharma Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Gland Pharma Limited?

Gland Pharma Limited has a P/E of 53.1 and a return on equity of 10.53%.

What is the stock symbol of Gland Pharma Limited?

Gland Pharma Limited is listed on the NSE under the symbol GLAND and on the BSE under the scrip code 543245.

How has Gland Pharma Limited's share price moved over the past year?

Gland Pharma Limited's share price is up 75.6% over one year and up 12.4% over three months. Its 52-week range is ₹1,573.60 to ₹3,374.00.

What were Gland Pharma Limited's latest quarterly results?

In Q2 FY27, Gland Pharma Limited reported revenue of ₹1,834 Cr and net profit of ₹291 Cr, with basic EPS of ₹17.62 (consolidated, parsed from the company's exchange filing).

How have Gland Pharma Limited's revenue and profit changed over the past year?

Gland Pharma Limited reported revenue of ₹1,834 Cr in Q2 FY27, up 23.3% from ₹1,487 Cr in Q2 FY26 and up 1.9% from ₹1,800 Cr in Q1 FY27.

What is the promoter holding in Gland Pharma Limited?

Promoters held 45.75% of Gland Pharma Limited's shares as of Sept 2026, against 51.83% in Sept 2025 (−6.08 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.